As of May 2012, Vietnam continues to see sustained high incidence of hand, foot and mouth disease (HFMD) since the beginning of the year. China, Hong Kong (China), Macao (China) and Singapore have been reporting an increase in number of cases.
WHO “SAVE LIVES: Clean Your Hands” is an annual campaign that makes part of major global effort to support healthcare workers to improve hand hygiene practices in healthcare settings, and thus support the prevention of often life-threatening healthcare-associated infections.
This study, strong of an almost complete follow-up of all children born in Denmark from 2003 to 2008, provides evidence that the DTaP-IPV-HiB vaccine is not associated to an overall increased risk of febrile seizures and epilepsy.
This workshop enabled all to agree on the relevance of EPIS VPD to be used as a platform for the reporting and monitoring of measles outbreak in the EU, agree on the type of information to be reported, the nature of outbreaks to be notified and the further usage by ECDC (e.g. European Monthly Measles Monitoring1) and other Member States of data that will be shared through EPIS VPD by countries.
The European Food Safety Authority (EFSA) and the European Centre for Disease Prevention and Control (ECDC) have published the second joint EU report on antimicrobial resistance in zoonotic bacteria affecting humans, animals and food.
The European Food Safety Authority (EFSA) and the European Centre for Disease Prevention and Control (ECDC) have published their annual report on zoonoses and food-borne outbreaks in the European Union for 2010.
A meeting and a workshop on the ECDC point prevalence survey (PPS) of healthcare-associated infections and antimicrobial use in acute care hospitals took take place in London on 5-6 March 2012.
The coordination of European FWD outbreaks can be difficult to manage. In order to help Member State countries with the task, ECDC is launching an online toolkit which provides investigators with a series of tools for the investigation of an outbreak that involves at least two EU Member States.
4CMenB has the potential to reduce serogroup B meningococcal disease substantially. Despite its potential, the vaccine may have some limitations, and it remains to be seen if booster doses will be required to sustain protection.